These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14594523)

  • 21. Galantamine: use in Alzheimer's disease and related disorders.
    Bullock R
    Expert Rev Neurother; 2004 Mar; 4(2):153-63. PubMed ID: 15853556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
    López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E
    Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
    Rockwood K; Dai D; Mitnitski A
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current antidementive therapy].
    Perneczky R; Kurz A
    MMW Fortschr Med; 2004 May; 146 Spec No 2():53-6. PubMed ID: 15376702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
    Freund-Levi Y; Bloniecki V; Auestad B; Tysen Bäckström AC; Lärksäter M; Aarsland D
    Dement Geriatr Cogn Disord; 2014; 38(3-4):234-44. PubMed ID: 24969380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.
    Erkinjuntti T; Román G; Gauthier S
    J Neurol Sci; 2004 Nov; 226(1-2):63-6. PubMed ID: 15537522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
    Edwards K; Royall D; Hershey L; Lichter D; Hake A; Farlow M; Pasquier F; Johnson S
    Dement Geriatr Cogn Disord; 2007; 23(6):401-5. PubMed ID: 17409748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
    Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Galantamine in Alzheimer's disease.
    Razay G; Wilcock GK
    Expert Rev Neurother; 2008 Jan; 8(1):9-17. PubMed ID: 18088197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapy approaches in cerebral cognitive deficits--neuropsychiatric aspects].
    Reisecker F
    Wien Med Wochenschr; 1996; 146(21-22):546-8. PubMed ID: 9092214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacokinetics of galantamine.
    Farlow MR
    Clin Pharmacokinet; 2003; 42(15):1383-92. PubMed ID: 14674789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galantamine introduced in Europe.
    Am J Alzheimers Dis Other Demen; 2001; 16(1):8. PubMed ID: 11416951
    [No Abstract]   [Full Text] [Related]  

  • 34. Galantamine: a new treatment for Alzheimer's disease.
    Wilkinson DG
    Expert Rev Neurother; 2001 Nov; 1(2):153-9. PubMed ID: 19811027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Emelin AIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):25-33. PubMed ID: 18427456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meeting the challenges of vascular dementia. Introduction.
    Small G
    Int J Clin Pract Suppl; 2001 May; (120):1-4. PubMed ID: 11406921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Efficacy of Galantamine in Alzheimer's Disease: The Okayama Galantamine Study (OGS).
    Nakano Y; Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Sato K; Deguchi K; Abe K
    J Alzheimers Dis; 2015; 47(3):609-17. PubMed ID: 26401696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease.
    Patterson CE; Passmore AP; Crawford VL
    Int J Clin Pract; 2004 Feb; 58(2):144-8. PubMed ID: 15055862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology.
    Coyle JT; Geerts H; Sorra K; Amatniek J
    J Alzheimers Dis; 2007 Jul; 11(4):491-507. PubMed ID: 17656829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment options: the latest evidence with galantamine (Reminyl).
    Erkinjuntti T
    J Neurol Sci; 2002 Nov; 203-204():125-30. PubMed ID: 12417370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.